Answers are grounded in this paper and cite their sources.
Pharmaceutical research on new anticancer drugs continues in two directions: a ‘prospective’ one involving the selection of compounds acting on ‘new’ biological targets; and a ‘conservative’ one involving the selection of chemotherapeutic agents acting on ‘validated’ targets. Clinical interest in paclitaxel (Taxol™) and docetaxel (Taxotere™) has led to a reactivation of research on agents that bind tubulin/microtubules. Several new antimitotic compounds were presented at the American Association for Cancer Research meeting in Toronto, last April.
No takes yet. Share an insight, caveat, or question.
François Lavelle (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: